Navigation Links
Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
Date:7/17/2008

nging trial will include three treatment arms of anastrozole, all with a fixed dose oral contraceptive in pre-menopausal women diagnosed with endometriosis. The primary endpoint is reduction in endometriosis-related symptoms, primarily pain. Secondary endpoints include quality of life, bleeding patterns and safety outcomes. The goal of the study is to provide data on efficacy and safety of MPI-676, as well as information about feasible endpoints and trial sizes for the planning and execution of the subsequent pivotal Phase III program in endometriosis.

Endometriosis is a serious medical condition where endometrial stroma and glands that are normally present in the uterine cavity are found in other parts of the body. Endometriosis lesions can be found anywhere in the pelvic cavity. The most common symptom of endometriosis is pelvic pain, which often correlates to the menstrual cycle, but a woman with endometriosis may also experience pain that doesn't correlate to her cycle. For many women, the pain of endometriosis is so severe and debilitating that it significantly impacts their daily lives.

It is estimated that seven to 10 percent of all women are affected by endometriosis, including 70 to 87 percent of women with chronic pelvic pain and 30 to 40 percent of all infertile women. Chronic pelvic pain, dysmenorrhea (painful periods) and dyspareunia (painful intercourse) are common symptoms of women with endometriosis. There are several medical treatment options, including danazol, GnRH agonists and progestins, each of which have limitations associated with patient response, tolerability, side-effect profile and duration of treatment.

About Femathina(TM) (MPI-674) and MPI-676

Femathina(TM) (MPI-674) and MPI-676 are based on anastrozole, an aromatase inhibitor (AI) with well-established, multi-year chronic safety and tolerability data. AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibi
'/>"/>

SOURCE Meditrina Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
4. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
5. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
6. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
7. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
8. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
9. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Mass. , July 29, 2014  Instrumentation Laboratory (IL) ... including a new corporate logo. This is part of a ... Founded in Boston, MA , ... family of companies since 1992.  Other companies in the group ... Biokit and Systelab ( Barcelona, Spain ).  Like ...
(Date:7/29/2014)... LINCOLNSHIRE, Ill. , July 29, 2014  Sysmex ... equipment and information systems technology, will feature an exhibit ... (AACC) Annual Meeting and Clinical Lab Expo in ... 31, 2014. "We are extremely excited ... tremendous opportunity to interact with our customers and continue ...
(Date:7/29/2014)... LAKE CITY , July 29, 2014  The ... The Grand American Hotel in Salt Lake ... speakers representing some of most respected healthcare organizations in ... Health Catalyst , is an industry conference devoted to ... healthcare analytics,  an essential element of both accountable care ...
Breaking Medicine Technology:Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5
... Top-Line Data Expected in the Third Quarter --, ... VIAP ), a biotechnology company focused on the development ... that,it has completed the last patient visit in its ... be analyzed to determine,VIA-2291,s effect on inflammation, and the ...
... Modigene,s CTP Technology for Extending ... of Action of Therapeutic Proteins -, NES-ZIONA, Israel, ... noted the successful completion of a Phase,III clinical trial ... uses the naturally occurring CTP,peptide to extend the duration ...
Cached Medicine Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 5Modigene Platform Validated in Independent Phase III Trial of CTP Technology 2Modigene Platform Validated in Independent Phase III Trial of CTP Technology 3
(Date:7/29/2014)... Colorado (PRWEB) July 29, 2014 The ... Gossip reveals the inside story to Gary M. Levin’s ... a remarkable cure method for this serious disorder. Levin ... most discouraging conditions that can be found in patients. ... MD and surgeon. For many years, Levin has worked ...
(Date:7/29/2014)... Winter is here down under, and ... Sydney’s central business district. That is, until a troop ... the otherwise ordinary day into a celebration—a celebration of ... advocates of The Truth About Drugs, a drug prevention ... They woke up the city with a rousing performance ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Daily Gossip reveals ... 5 step holistic system that will permanently eliminate all the ... Coleman his natural treatment will banish symptoms such as mild ... beeping sound heard by patients will be gone forever. , ... 60 days. The author of this program says that at ...
(Date:7/29/2014)... TUESDAY, July 29, 2014 (HealthDay News) --,The time at ... affect their chances for survival, new research suggests. ... weekends or during holidays is associated with a 13 ... business hours, researchers report. Every year, more than ... most severe type of heart attack, which is caused ...
(Date:7/29/2014)... the bite of a brown recluse spider is poisonous, ... expert notes. It,s still important to recognize the ... recluse spider bite, warned Dr. Donna Seger, medical director ... dangerous bites are on the rise. "As physicians, ... [bite] has classic characteristics, but if physicians are not ...
Breaking Medicine News(10 mins):Health News:Natural Multiple Sclerosis Treatment Review Reveals the Inside Story to Gary M. Levin’s Cure Program 2Health News:Sydney Business District “Rocked” by The Truth About Drugs 2Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2
... Aeras and the China National Biotech Group (CNBG) today ... organizations to pursue opportunities to jointly develop tuberculosis (TB) vaccines ... The partnership is intended to leverage both organizations, capabilities ... a major public health priority in China, where there are ...
... Serena Gordon HealthDay Reporter , MONDAY, July 25 (HealthDay ... worry to add to their list: Kids younger than 10 years ... on their own. New research found that while children ... the street solo -- they do stop and look both ways ...
... specific genes shuts down the mass production of antibodies launched ... by scientists at The University of Texas MD Anderson Cancer ... "Regulatory T cells prevent unwanted or exaggerated immune system ... been unclear," said paper senior author Chen Dong, Ph.D., professor ...
... ALBUQUERQUE, N.M. Americans are used to drinking from ... water utilities might be vulnerable to terrorist attacks or ... an open-source software developed by Sandia National Laboratories ... public water systems can be protected through enhanced detection ...
... , MONDAY, July 25 (HealthDay News) -- As ... school this fall, the American Lung Association urged parents to ... and help ease their transition back to the classroom. ... back-to-school necessities, it is even more essential for parents of ...
... of oncologists in the Program in Women,s Oncology at Women ... guide to the human papilloma virus (HPV) so physicians can ... women with the virus. Dx/Rx: Human Papilloma Virus was ... oncology at Women & Infants and associate professor of obstetrics ...
Cached Medicine News:Health News:Aeras and China National Biotech Group sign memorandum of understanding for TB vaccine R&D 2Health News:Kids With ADHD Less Adept at Crossing the Street: Study 2Health News:Kids With ADHD Less Adept at Crossing the Street: Study 3Health News:Specialized regulatory T cell stifles antibody production centers 2Health News:Specialized regulatory T cell stifles antibody production centers 3Health News:Sandia's CANARY software protects water utilities from terrorist attacks and contaminants 2Health News:Sandia's CANARY software protects water utilities from terrorist attacks and contaminants 3Health News:Preparation Key When Kids With Asthma Go Back to School 2Health News:Oncologists publish HPV manual for physicians 2
The Oscor PACE 101 H is an external single chamber cardiac demand pacemaker. The PACE 101 H feature an option for a atrial overdrive stimulation....
... quadripolar pacing wire design offers ... sensing in the atrium and ... wires in one lead design. ... and ventricle are color-coded for ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: